We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Kyowa Hakko Kirin Co. Ltd. ADR Annual stock financials by MarketWatch. View the latest KYKOY financial statements, income statements and financial ratios. Skip to main content Main Menu Latest News ...

Access Kyowa Kirin stock price history with daily data, historical prices, all-time highs, and stock chart history. Download and analyze trends easily.

The U.S. Food and Drug Administration (FDA) accepted the New Drug Application (NDA) for ziftomenib, an investigational treatment pursued by Kura Oncology, Inc. (NASDAQ:KURA) and Kyowa Kirin ...

“The FDA’s acceptance of our New Drug Application marks a significant milestone for Kura and Kyowa Kirin and, more importantly, for patients living with this genetic subset of AML, who face an ...

– Consistent efficacy with comparable CR/CRh rates and clinically meaningful MRD-negative responses across pre-specified subgroups, regardless of prior HSCT, prior venetoclax, or FLT3/IDH co ...

– Potential first approval of a menin inhibitor for the treatment of adult patients with relapsed or refractory AML with an NPM1 mutation – SAN DIEGO and TOKYO, June 01, 2025 (GLOBE NEWSWIRE ...

“The FDA's acceptance of our New Drug Application marks a significant milestone for Kura and Kyowa Kirin and, more importantly, for patients living with this genetic subset of AML, who face an ...